Complications and risk factors after allogeneic hematopoietic stem cell transplantation

    loading  Checking for direct PDF access through Ovid

Abstract

BACKGROUND:

Effective prevention and treatment of complications after allogeneic hematopoietic stem cell transplantation is an important factor to improve patient survival.

OBJECTIVE:

To analyze complications and risk factors after allogeneic hematopoietic stem cell transplantation.

METHODS:

Based on literature search, relevant articles concerning complications after allogeneic hematopoietic stem cell transplantation were retrieved and analyzed. Here, we analyzed common complications after allogeneic hematopoietic stem cell transplantation, such as pulmonary complications, fungal sepsis, cytomegalovirus infections, and central nervous system complications.

RESULTS AND CONCLUSION:

Pulmonary complications with a higher mortality are commonly seen after allogeneic hematopoietic stem cell transplantation. The pathogenesis of pulmonary complications may be associated with graft-versus-host disease and cytomegalovirus antigenemia. The main pathogen of fungal sepsis after allogeneic hematopoietic stem cell transplantation is Candida, also with a higher mortality. Therefore, second preventive and early empirical antifungal therapy should be performed. Ganciclovir and foscarnet are effective in the treatment of cytomegalovirus infections after allogeneic hematopoietic stem cell transplantation. Incidence of central nervous system complications after allogeneic hematopoietic stem cell transplantation is relatively low, but the course of treatment cannot be ignored. Complications after allogeneic hematopoietic stem cell transplantation are associated with multiple risk factors. During the clinical treatment, preventive measures for relevant factors should be taken to reduce the incidence of complications and improve patient survival.

Subject headings:

stem cells; stem cell transplantation; hematopoietic stem cells; hematopoietic stem cell mobilization; hematopoietic stem cell transplantation; graft vs host disease

Funding:

the National Natural Science Foundation of China, No. 31200686*

Related Topics

    loading  Loading Related Articles